Drug Approval | October 04, 2021
Biocon launches Everolimus tablets in the US
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
The company plans to submit the IND application by the end of 2021
TCS to help Apoteket drive its digital transformation across sales channels and internal processes
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
Prostate cancer is the second-most common cancer in men and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low
Remote screening of diabetic retinopathy can help in early detection, even before there are any noticeable vision changes
The company does not expect the outcome of this inspection to impact its plans
Subscribe To Our Newsletter & Stay Updated
